Neuronetics Management
Management criteria checks 1/4
Neuronetics' CEO is Keith Sullivan, appointed in Jul 2020, has a tenure of 4.33 years. total yearly compensation is $2.99M, comprised of 23.4% salary and 76.6% bonuses, including company stock and options. directly owns 2.44% of the company’s shares, worth $593.60K. The average tenure of the management team and the board of directors is 1.8 years and 4.3 years respectively.
Key information
Keith Sullivan
Chief executive officer
US$3.0m
Total compensation
| CEO salary percentage | 23.4% |
| CEO tenure | 4.3yrs |
| CEO ownership | 2.4% |
| Management average tenure | 1.8yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Neuronetics, Inc. (NASDAQ:STIM) Analysts Just Slashed Next Year's Revenue Estimates By 12%
Nov 18
A Piece Of The Puzzle Missing From Neuronetics, Inc.'s (NASDAQ:STIM) 28% Share Price Climb
Nov 05Investors Give Neuronetics, Inc. (NASDAQ:STIM) Shares A 60% Hiding
Aug 13Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet
May 24The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 09Neuronetics: Reality Set In
May 09Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower
May 08Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?
May 01Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely
Mar 17Neuronetics: Modest Improvements Are Not Enough
Jan 30Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward
Dec 19Neuronetics, Inc.'s (NASDAQ:STIM) Shares Not Telling The Full Story
Jun 21Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet?
May 10Neuronetics: Growth To Capture, But Fairly Priced
Sep 06Is Neuronetics (NASDAQ:STIM) Using Debt Sensibly?
Sep 06Neuronetics gets FDA nod for its D-Tect accessory product for use to treat depression
Aug 29Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M , revises FY guidance
Aug 02Neuronetics stock soars 30% as FDA clears NeuroStar system for anxious depression
Jul 19Is Neuronetics (NASDAQ:STIM) A Risky Investment?
Jun 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$36m |
| Jun 30 2024 | n/a | n/a | -US$32m |
| Mar 31 2024 | n/a | n/a | -US$28m |
| Dec 31 2023 | US$3m | US$700k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$33m |
| Jun 30 2023 | n/a | n/a | -US$31m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$2m | US$676k | -US$37m |
| Sep 30 2022 | n/a | n/a | -US$37m |
| Jun 30 2022 | n/a | n/a | -US$37m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$3m | US$650k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$27m |
| Jun 30 2021 | n/a | n/a | -US$22m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$4m | US$280k | -US$27m |
Compensation vs Market: Keith's total compensation ($USD2.99M) is above average for companies of similar size in the US market ($USD653.78K).
Compensation vs Earnings: Keith's compensation has increased whilst the company is unprofitable.
CEO
Keith Sullivan (66 yo)
4.3yrs
Tenure
US$2,990,985
Compensation
Mr. Keith J. Sullivan has been President, Chief Executive Officer and Director of Neuronetics, Inc. since July 14, 2020. Mr. Sullivan has been a Director of Venus Concept Inc. (formerly known as Restoratio...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.3yrs | US$2.99m | 2.44% $ 593.6k | |
| Executive VP | 5.3yrs | US$1.36m | 0.85% $ 206.1k | |
| Executive VP | 4.8yrs | US$1.16m | 0.60% $ 146.3k | |
| Senior VP of Operations & Quality | 1.8yrs | no data | no data | |
| Senior VP & Chief Marketing Officer | 1.5yrs | no data | no data | |
| Senior VP & Chief Revenue Officer | 1.8yrs | no data | no data | |
| Senior Vice President of National Accounts | 1.8yrs | no data | no data | |
| Senior Vice President of R&D and Clinical | 1.8yrs | no data | no data |
1.8yrs
Average Tenure
60yo
Average Age
Experienced Management: STIM's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.3yrs | US$2.99m | 2.44% $ 593.6k | |
| Independent Director | 7.3yrs | US$182.50k | 0.67% $ 163.3k | |
| Independent Director | 5.1yrs | US$175.00k | 0.26% $ 63.1k | |
| Independent Chairman of the Board | 3.6yrs | US$245.00k | 1.06% $ 258.3k | |
| Independent Director | 3.3yrs | US$162.50k | 0.28% $ 68.9k |
4.3yrs
Average Tenure
65yo
Average Age
Experienced Board: STIM's board of directors are considered experienced (4.3 years average tenure).